期刊
ADVANCED FUNCTIONAL MATERIALS
卷 30, 期 7, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.201906922
关键词
cancer immunotherapy; chemoimmunotherapy; drug delivery; hydrogel
类别
资金
- Soochow University
- Program for Jiangsu Specially Appointed Professors
- Collaborative Innovation Center of Suzhou Nano Science and Technology, the 111 Project
- National Natural Science Foundation of China [31900988, 81772773, 81672560, 81302275]
- Natural Science Foundation of Jiangsu Province [SBK2019040088]
- Jiangsu Province Six Talent Peaks Project [SWYY-110]
- Jiangsu Provincial Medical Youth Talent [QNRC2016753]
- Project of Jiangsu Provincial Maternal and Child Health Association [FYX201709]
- Gusu Medical Talent Project [GSWS2019034]
- Postgraduate Research & Practice Innovation Program of Jiangsu Province [SJCX18_0853]
Unsatisfied cytoreductive surgery predicts worse clinical outcomes. Previous studies have found that cyclophosphamide (CTX) is a rhythmic immune modulator that can target suppressive regulatory immune cells and meanwhile enhance effector cells. Here, a therapeutic scaffold is engineered based on a fibrin hydrogel to codeliver CTX and anti-PD-L1 antibody (aPDL1) for the prevention of cancer recurrence postsurgery. It is demonstrated that the sequential release of CTX and aPDL1 from the fibrin hydrogel can lead to selective depletion of regulatory T cells (Treg) in the residual tumor, which would then synergize the immune checkpoint blockade therapy. The therapeutic benefit is demonstrated in an orthotopic breast tumor and an orthotopic ovarian tumor model after incomplete resection of primary tumors. In this work, the strategy provides a clinically valuable option for preventing cancer recurrence postsurgery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据